West Virginia University
Institutional Biosafety Committee Meeting Minutes
August 2025

DATE: 08/25/25
TIME: 3:00pm
LOCATION: BMRF 101 with a Zoom option

The August meeting of the West Virginia University Institutional Biosafety Committee (IBC) was called to order by Karen Martin at 3:00 PM. The meeting was open to the public with public notification on the university's IBC website.

MEETING ATTENDANCE

Committee members present for the meeting were (role/expertise noted, as applicable):

1. Karen Martin, IBC Chair
2. Matt Stinoski, Institutional Biosafety Officer
3. Josh Parenti, Associate Biosafety Officer
4. Mariette Barbier
5. Kathy Brundage
6. Marcus Cervantes, Occupational Health Representative
7. Tara Cotroneo, Animal containment expert
8. John Hando
9. Ivan Martinez
10. Dan Panaccione, Plant expert
11. Chris Waters
12. Dylan Willis

Non-committee Members: none

A majority of the committee was present; therefore, a quorum was established.

***PREVIOUS MEETING* MINUTES REVIEW**

A copy of the July IBC minutes was emailed to committee members for review prior to the meeting. A typographical error was noted and will be corrected. A motion was made to accept the minutes, as written, following the correction of the typographical error. The minutes were unanimously approved.

OPEN DISCUSSION

Reminder to sign committee appointment letters and return if you were sent one.

IBC Meeting Minutes - After June's minutes were approved by the committee, the BSO shared with them the WVU Legal Team for them to determine what can and/or should be redacted, the minutes are currently in Legal review. The BSO will compare our minutes to other university minutes for guidance to determine if our version is similar for publication. Some committee members have expressed concerns with the content that will be be posted in our minutes and available to the public following publication.

PROTOCOLS FOR REVIEW

Protocol # (New/Renewal/Amendment)	**25-08-01 (new)**
Protocol Title	**Diagnostic and therapeutic uses of focused ultrasound in a rap epilepsy mode.**
PI Name	**Konrad, Peter**
Biohazards	***Recombinant nucleic acids*** **Type of genes:** *N/A* **Type of vector**: N/A **Applicable NIH guidelines:** N/A ***Human, animal, or plant pathogens*:** *N/A* ***BBP & OPIM*:** N/A ***Introduction into Animals*** **Species:** rat **Material:** *Tetanus toxin*
Proposed Biosafety Level	BSL2
Reviewer Summary	This protocol will evaluate focused ultrasound technology for use in diagnostic and therapeutic uses in epilepsy. It will utilize tetanus toxin to induce seizures in a rat model.

There was a motion to approve the amendment at BSL2, pending the below IBC recommended revisions:

Page 2 - Add biosafety cabinet dates.

On personnel table, add more details for project responsibility other than "all" Like toxin injection, necropsy, etc.

Page 3 - How are lab coats laundered? We require the use of a cleaner that utilizes Universal Precautions (Massulo's or Model).

Page 6 (toxin) - For exposure response, please add that the Biosafety Officer will be contacted in the event of an exposure.

Materials & Methods - Reconstitution take place in a fume hood or biosafety cabinet. Rename biosafety hood to biosafety cabinet throughout. Will reconstitution take place in same room as injection? If not, liquid should be transported in secondary containment, please specify. Formalin fixation should occur in a fume hood.

The motion was unanimously approved.

Protocol # (New/Renewal/Amendment)	**17-06-04 (renewal)**
Protocol Title	**Examination of the bactericidal effects of antimicrobial agents on MRSA and MSSA**
PI Name	**Li, Bingyun**
Biohazards	***Recombinant nucleic acids*** **Type of genes:** N/A **Type of vector**: N/A **Applicable NIH guidelines:** N/A ***Human, animal, or plant pathogens*:** *Staphylococcus aureus* ***BBP & OPIM*:** human cell lines ***Introduction into Animals*** **Species:** N/A **Material:** N/A
Proposed Biosafety Level	BSL2, BSL2+ for MRSA
Reviewer Summary	This protocol renewal will continue to evaluate antimicrobial agents against MRSA and MSSA infections related to periprosthetic joints. It will utilize murine osteoblasts and S. aureus cultures.

There was a motion to approve the amendment at BSL2, BSL2+ for MRSA, pending the below IBC recommended revisions:

Page 2 -Personnel table, fill out all sections

Page 3 - WVU does not have on site lab coat laundering. Use Massulo's or Model or WVUH

Page 5 (pathogen) - For exposure response, please add that the Biosafety Officer will be contacted in the event of an exposure.

Please send antibiotic susceptibility test results for MRSA strains.

Material and Methods: Please add the additional information:

Handling of MRSA
These additional measures will be implemented when handling MRSA.

1. The door to the lab will be kept closed while conducting all experimental procedures. All experiments will be carried out within our full enclosed dedicated cell culture. The door to the room is marked with a BSL2+ tag.
2. Two pairs of gloves will be worn when handling MRSA. The outer pair will be discarded in the biohazard waste during procedures as necessary and afterwards when manipulations are complete.
3. Laboratory staff will wear a solid-front disposable lab coat during all manipulations.
4. All work will be conducted inside a BSL2 biosafety cabinet.
5. Sealed centrifuge rotors or buckets will be opened, loaded and unloaded with samples inside the biosafety cabinet.

APPROVAL FOR ADJOURNMENT

There was a motion to adjourn the meeting if there were no further items for discussion. The meeting was adjourned at 3:25 PM.